Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)
European Journal of Cancer2014Vol. 50(18), pp. 3116–3124
Citations Over TimeTop 14% of 2014 papers
Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, Pascal Artru, Mélanie Gauthier, Thierry Lecomte, Thomas Aparicio, Anne Thirot‐Bidault, Céline Lobry, Amani Asnacios, Sophie Manet-Lacombe, Francine Fein, Olivier Dubreuil, Bruno Landi, Aziz Zaanan, Franck Bonnetain, Julien Taı̈eb
Related Papers
- → Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study(2008)27 cited
- → FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study.(2020)3 cited
- → Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype(2017)2 cited
- → Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trial(2004)2 cited
- → Sequential or combination chemotherapy for a patient with mCRC?(2008)